Teva Pharmaceuticals Romania reported a 15 percent turnover increase in the first quarter of the year, to 3.5 million dollars, compared with the same period last year, and estimates an around 60 percent increase for the entire year, to over 20 million dollars.
During the first three months of 2007, Teva Romania’s turnover amounted to 2.5 million dollars.
"For this year, we forecast an around 60 percent increase, which will be prompted both by sales of existing products and by new products. Last year, we launched 34 products," said general manager of Teva Pharmaceuticals Romania, Dana Stanciulescu. She expects to preserve the upward trend for products that treat osteoporosis and multiple sclerosis, and an increase for products related to oncology, the cardiovascular system, the central nervous system and organ transplants.
"Up until a year ago, Teva was identifiable through two products, which accounted for 70 percent of the company’s turnover, while this year, we expect them to account for just 25 percent," said Stanciulescu.
In 2007, the company posted turnover worth 16 million, after oncologic products accounted for almost 25 percent, i.e. 3.5 million dollars. The company has plans to launch 20 new products on the cardiovascular, diabetes, neurology, oncology and transplant-related segments.